Peters H J
Med Klin. 1979 Jul 6;74(27):1063-6.
The aminoglycoside dibekacin, developed in Japan and now on the market in Germany, has been tested for its clinical and microbiological effectiveness on 45 patients with highly resistant germs. 41 of the 55 primary sensitive germs could be thus eliminated from the urine, 6 of the 11 being pseudomonas germs. The clinical results of 33 of the 45 patients were very good, only 4 of them were not convincing. The nephrotoxic side effects were noticeably slight. No evidence of damage to the VIIIth brain nerve was observed in these patients. The results were satisfactory considering the selection of problem patients in the test group. Dibekacin can be regarded with gentamicin as a first choice aminoglycoside.
氨基糖苷类药物双去氧卡那霉素由日本研发，目前已在德国上市。该药物针对45例感染高度耐药菌的患者进行了临床和微生物学有效性测试。在55种原发性敏感菌中，有41种可从尿液中清除，其中11种中的6种为假单胞菌。45例患者中有33例临床效果非常好，只有4例效果不明显。肾毒性副作用明显轻微。在这些患者中未观察到第八对脑神经受损的迹象。考虑到试验组中问题患者的选择，结果令人满意。双去氧卡那霉素可与庆大霉素一起视为首选氨基糖苷类药物。
